chrisvoncsefalvay/vaers-outcomes huggingface dataset:
I had a slight ache where the needle was placed after I was given the shot.  It was not severe. Next 10 days I did not have any symptoms. At the night of the 10th day, I had a little chill, fatigue and joint pain on the fingers and the toes. Next 14 days, My joint pain on the same area and fatigue continued about at the same rate from the 10th night.  On the 15th day, my joint pain was almost gone, a little bit of tiredness remains, I would not call this fatigue anymore.  On the 16th day, joint pain was gone.  and after 30 minutes of nap, the tiredness is gone.
Erythematous papules vesicle. Cetirizine for 4-5 day advised.
I had runny nose, stuffy nose, I did not have fever at all, I had a persistent cough. It was not moist cough. On 03/2/2023 I took a PCR COVID-19 test at an urgent care and the results were positive.  I had a telehealth visit with urgent care on 03/3/2023 and was prescribed Paxlovid.  I started Paxlovid on 3/3/2023 and continued that for the 5 days. I also received a cough medicine, Benzonatate. I could take it as much as 3 times a day. Within a couple of days, I was significantly better the cough persisted for at least 10 day and it got better and better.
Patient experienced a vagal response approximately 5 minutes after receiving the vaccine.  Patient transported to ED via EMS - seen and discharged.
This case was reported by a pharmacist via call center representative and described the occurrence of extensive swelling of vaccinated limb in a 82-year-old female patient who received SHINGRIX for prophylaxis. On 16th July 2018, the patient received the 1st dose of SHINGRIX. On an unknown date, less than a year after receiving SHINGRIX, the patient experienced extensive swelling of vaccinated limb and erythema. On an unknown date, the outcome of the extensive swelling of vaccinated limb and erythema were recovered/resolved. It was unknown if the reporter considered the extensive swelling of vaccinated limb and erythema to be related to SHINGRIX. Additional information was reported as follows: The healthcare professional was unable to provide with the batch number and expiry date at the time of reporting. The patient experienced redness and swelling from the shoulder to hand after vaccination with the first dose of SHINGRIX.
favoring rt leg while walking;lt thigh (around shot site) tender to touch about 1wk;
Dizziness/vertigo  for 36 hours. Was bad enough that I just day slept or sat in a chair for 36 hours. No vomiting. Dizziness is getting less as of 11:30am,  August 1st.  Benadryl and Meclizine taken
Chills; Pain in the entire body; Joint pain; This spontaneous case was reported by a consumer and describes the occurrence of CHILLS (Chills), MYALGIA (Pain in the entire body) and ARTHRALGIA (Joint pain) in an 83-year-old male patient who received mRNA-1273 (Spikevax) (batch no. 0223J21A) for COVID-19 vaccination.     Concurrent medical conditions included Glaucoma (Started 10 years ago.), Leg cramps, Muscle pain, Tinnitus (Start Date: at the age of 45) and Spinal disorder NOS (Started at the age of 45.). Concomitant products included IBUPROFEN (ADVIL [IBUPROFEN]) for Muscle pain, ALPRAZOLAM (XANAX) for an unknown indication.   On 03-Mar-2022, the patient received first dose of mRNA-1273 (Spikevax) (Intramuscular) 1 dosage form. On 31-Mar-2022, received second dose of mRNA-1273 (Spikevax) (unknown route) dosage was changed to 1 dosage form. On 01-Apr-2022, the patient experienced CHILLS (Chills), MYALGIA (Pain in the entire body) and ARTHRALGIA (Joint pain). The patient was treated with IBUPROFEN (ADVIL [IBUPROFEN]) for Myalgia, at a dose of 2 Advil pills of 200mg each, and 1 more pill during the afternoon. On 01-Apr-2022, CHILLS (Chills), MYALGIA (Pain in the entire body) and ARTHRALGIA (Joint pain) had resolved.            The patient was using 3 different glaucoma drops concomitantly.  After getting 1st dose, patient did not experience any symptom. After the 2nd dose patient woke up at 5 a.m. in the morning experienced events. Patient stayed in bed all day.
Received varicella vaccine 12/19/99. Diagnosed with chicken pox 4/17/06.
FLUSHNESS; FACIAL REDNESS; JAW SORENESS; LETHARGIC; SEVERE  HEADACHE; This spontaneous report received from a patient concerned a patient of unspecified age and sex. The patient's weight, height, and medical history were not reported. The patient experienced rash when treated with clopidogrel bisulfate, and swelling reaction when treated with benzylpenicillin. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, intramuscular, batch number: 1805022, and batch number: 1805022 expiry: UNKNOWN) .5 ml, administered on 07-MAR-2021 to Left Arm for prophylactic vaccination. No concomitant medications were reported. On 07-MAR-2021, the subject experienced flushness. On 07-MAR-2021, the subject experienced facial redness. On 07-MAR-2021, the subject experienced jaw soreness. On 07-MAR-2021, the subject experienced lethargic. On 07-MAR-2021, the subject experienced severe headache. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient was recovering from severe headache, flushness, facial redness, jaw soreness, and lethargic. This report was non-serious.
Pt reports feeling generalized body aches since receiving covid-19 vaccine which she reports has not subsided in the past 4 days.
Information has been received from a 73 year old female patient reporting on herself. There was no information about the patient's concurrent conditions, medical history, drug reactions/allergies or concomitant medication. On 29-SEP-2017, the patient was vaccinated with PNEUMOVAX 23 for prophylaxis (dose, route of administration, lot number and expiration date were not reported).  On 29-SEP-2017, the patient experienced swelling, tenderness and heat (feeling hot) about 4 inches below the injection site. There was no swelling or anything at the injection site. On 30-SEP-2017, the patient developed a fever and nausea and on the next day, reported as on 01-OCT-2017, the patient developed diarrhea. On an unspecified date in 2017, the patient did not longer experience swelling, tenderness and heat where it first appeared (resolved), but "it was itchy" and the swelling, tenderness and heat was appearing below her elbow on the same arm. At the reporting time, the fever, nausea and diarrhea were "almost gone" (resolving).The patient sought medical attention and spoke with her doctor on the phone. The outcome of the events prutitus, swelling, tenderness and heat below her elbow was reported as not resolved. The reporter did not assess the causal relationship between the events and therapy with PNEUMOVAX 23 were not reported.
Dizzy; Slept all day; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection), administration date 26Mar2021 (Batch/Lot number: unknown) as dose number unknown, single for COVID-19 immunisation. The patient's relevant medical history and concomitant medications were not reported.  The following information was reported: FATIGUE (non-serious) with onset 26Mar2021, outcome "unknown", described as "Slept all day"; DIZZINESS (non-serious) with onset 27Mar2021, outcome "unknown", described as "Dizzy".  Additional information: The patient and his wife got the shot yesterday (at the time of reporting) and then woke up, yesterday they came home and slept all day. The patient was asking if that was normal but then this morning when he got up, he was very dizzy. The patient was asking if that was normal and if it was a side effect.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
pain in the left shoulder, exacerbated with any motion.  Over the following 2-3 days the pain improved somewhat.  However, pain remained with elevation of left upper extremity, any lifting involving left upper extremity, plus activities such as steering his car, turning over in bed, reaching over his head, and reaching to pull up the covers on his bed.
Itching at the injection site about a week after the first dose. Small round red area around injection site, no more than an inch in diameter. Itching is not constant and not severe. Only itches every once and a while.
ADVERSE REACTION OR SIDE EFFECT EXPERIENCED: NONE; PNEUMOCOCCAL VACCINE ON 29-MAR-2017 AND 02-APR-2018; This spontaneous report was received from a consumer and a physician referring a 64-year-old male patient. The patient's concurrent conditions included type 2 diabetes mellitus and congenital solitary kidney. The patient's family history included cirrhosis and alcoholism (father). The patient's historical conditions included chicken pox. The patient was a retired ex-tobacco user. The patient's historical immunizations included influenza virus vaccine (unspecified) (reported as Influenza) (on 15-OCT-2010 and 13-SEP-2016), diphtheria toxoid (+) pertussis acellular vaccine (unspecified) (+) tetanus toxoid (reported as tdap) (on 15-OCT-2010) and zoster vaccine live (ZOSTAVAX) (on 05-FEB-2015). The patient's historical drugs included valacyclovir hydrochloride, metoprolol tartrate, nitroglycerin, ticagrelor (BRILINTA), aspirin, atorvastatin and lisinopril. The patient's concomitant medications included aspirin, lisinopril (manufacturer unknown), atorvastatin, nebivolol hydrochloride (BYSTOLIC), and metformin.  On 17-DEC-2015, the patient experienced herpes zoster; and on 15-JAN-2016, he experienced acute myocardial infarction, acute coronary syndrome, coronary artery disease tear (all captured in reporting system # 2003USA004439).  On 29-MAR-2017, the patient was vaccinated with pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23) (dosage, anatomical location, route of administration, lot number and expiration date were not provided) for prophylaxis; and on 02-APR-2018, the patient was vaccinated with pneumococcal 13v conj vaccine (crm197)(PREVNAR 13) (dosage, anatomical location, route of administration, lot number and expiration date were not provided) (inappropriate schedule of product administration). It was reported that the patient did not experienced any adverse reactions or side effects as a result of both immunizations.; Sender's Comments:  US-009507513-2003USA004439:
Unwell; dizzy; Nauseous; This is a spontaneous report from a contactable consumer. This 50-year-old female consumer (patient) reported in response to Non-HCP letter sent that included that she received the second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; Solution for injection; Lot number: unknown) via an unspecified route of administration on an unknown date as dose 1, single for COVID-19 immunization. Patient's Medical History included left kidney removed donated (living donor) (05Nov2018-ongoing), appendectomy (1989) and gallbladder removal (2000). The patient's concomitant medications were not reported. The patient previously received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; Solution for injection; Lot number: unknown) via an unspecified route of administration on an unknown dose as dose 1, single for COVID-19 immunization and experienced nausea, was dizzy and fuzzy. It was mentioned that prior vaccinations and concomitant drugs were reported as none. Within first minutes she felt dizzy, nauseous and unwell. The patient received tylenol for treatment. Her second shot was worse than first and recovery was faster. On 01Feb2021, PCR was performed for which result was negative. On an unknown dates PCR was performed three times for which results were negative. The event of nausea was not recovered. The events malaise and dizziness were recovering. Information on lot/batch number had been requested.
A non-serious, spontaneous report of sneezing has been received from a consumer concerning a male patient, subsequent to receiving FLUMIST. No concomitant medications or medical history was provided. The patient received FLUMIST on 17-Sep-2010. On 18-Sep-2010, the patient experienced sneezing. The event of sneezing was ongoing at the time of the report.
first dose was given over a year ago; This case was reported by a other health professional via call center representative and described the occurrence of incomplete course of vaccination in a patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included shingrix (received 1st dose over a year ago in July 2021).   On an unknown date, the patient did not receive the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced incomplete course of vaccination. On an unknown date, the outcome of the incomplete course of vaccination was unknown.   Additional Information: GSK receipt date: 12-Oct-2022 Reporter's comment: The patient asked that if the first was given over a year ago, did the series need to be restarted. The patient wanted to be sure. Additional supportive information: Till the time of reporting, the patient did not receive second dose of Shingrix, which led to incomplete course of vaccination. The follow-up could not be possible as no contact details were available.
Markedly blurred vision on both eyes; This spontaneous case was reported by a consumer and describes the occurrence of VISION BLURRED (Markedly blurred vision on both eyes) in a 65-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 016M20A and #040A21A) for COVID-19 vaccination.     No Medical History information was reported.   On 18-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 16-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 19-May-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced VISION BLURRED (Markedly blurred vision on both eyes). At the time of the report, VISION BLURRED (Markedly blurred vision on both eyes) outcome was unknown.            Concomitant product use was not provided by the reporter.  Treatment information was not provided by the reporter.
Flu like symptoms. Daily drinker, fell down steps on day of presentation to ED. Found to have SAH, maxilla fx, zygomatic fx from trauma.
Pt broke out with a rash, about 12-15 lesions primarily on trunk and back with a few on the scalp.  Pt also had a low grade fever. Pt was diagnosed with chickenpox.
Swelling of the tongue without difficulty breathing; Malaise; Generalized raised red itchy rash; Generalized raised red itchy rash/Itchiness persisted for 2 days after the redness subsided; Fever; This spontaneous case was reported by a physician and describes the occurrence of SWOLLEN TONGUE (Swelling of the tongue without difficulty breathing), MALAISE (Malaise), RASH PRURITIC (Generalized raised red itchy rash), RASH ERYTHEMATOUS (Generalized raised red itchy rash/Itchiness persisted for 2 days after the redness subsided) and PYREXIA (Fever) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No medical history was provided by the reporter.     On 04-Oct-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced SWOLLEN TONGUE (Swelling of the tongue without difficulty breathing), MALAISE (Malaise), RASH PRURITIC (Generalized raised red itchy rash), RASH ERYTHEMATOUS (Generalized raised red itchy rash/Itchiness persisted for 2 days after the redness subsided) and PYREXIA (Fever). At the time of the report, SWOLLEN TONGUE (Swelling of the tongue without difficulty breathing), MALAISE (Malaise), RASH PRURITIC (Generalized raised red itchy rash), RASH ERYTHEMATOUS (Generalized raised red itchy rash/Itchiness persisted for 2 days after the redness subsided) and PYREXIA (Fever) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication listed.   No treatment information provided.
This is a spontaneous report from a contactable pediatrician via a Pfizer sales representative. A 4-month-old male patient was administered the second dose of PREVNAR 13 intramuscularly on 11Feb2011. The first dose of PREVNAR 13 was administered on 03Dec2010. Relevant concomitant medications were nystatin and albuterol. On 21Mar2011, at the age of 5 months, the patient had pressure equalizing tube placement. At this point, the patient had purulent ear discharge. On 15Apr2011, the patient was seen for purulent ear discharge. Culture test (15Apr2011) confirmed pneumococcal ear infection. On this day, the patient was administered the third dose of PREVNAR 13 along with the DTaP-Hib-IPV and rotavirus vaccine. On 21Apr2011, culture of the ear discharge above the PET was positive for scant growth streptococcal pneumoniae. Therapeutic measures taken in response to pneumococcal ear infection included treatment with CIPRODEX, then oral unspecified antibiotics. Outcome was unknown. The patient has not returned to the office. There are no etiological factors. Follow-up attempts completed. No further information expected. Follow-up (01Jun2011): New information reported from a contactable physician includes: updated medical history, concomitant medications, clinical course, treatment and causality assessment.
Abdominal pain; Chills; Fatigue; Vomiting; This spontaneous case was reported by a consumer and describes the occurrence of ABDOMINAL PAIN (Abdominal pain), CHILLS (Chills), FATIGUE (Fatigue) and VOMITING (Vomiting) in a 64-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concomitant products included LEVOTHYROXINE, PROPRANOLOL and LORAZEPAM for an unknown indication.    On 07-Apr-2021 at 12:30 PM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 07-Apr-2021, the patient experienced ABDOMINAL PAIN (Abdominal pain), CHILLS (Chills), FATIGUE (Fatigue) and VOMITING (Vomiting). The patient was treated with BISACODYL (DULCOLAX [BISACODYL]) at an unspecified dose and frequency. At the time of the report, ABDOMINAL PAIN (Abdominal pain), CHILLS (Chills), FATIGUE (Fatigue) and VOMITING (Vomiting) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Reporter did not allow further contact
This is an administration error.  Pt's first dose of SARS-CoV2 vaccine was Pfizer vaccine on May 27th.  Pt admitted to hospital at time due for 2nd dose.  Janssen vaccine incorrectly ordered and administered for patient's second dose of vaccine.  Pt did not have any immediate side effects, she was discharged from hospital <24 hours after vaccine error.  Patient and family informed of error.
Grandmother called states Lt thigh red swollen quarter to 50 cent size (DTA area) put cortisone cream (called BENADRYL 125mg 3ML every 6 hrs 4 oz).
Received covid19 vaccine Wednesday 2/3 ~1430. Worked until 7pm that day and was scheduled to work 7a-7p Thursday. On ride home Wednesday evening began to feel chills and body aches. Later during the night fever 99.8, and lethargic. Called out for shift following day and throughout the day had fatigue, intense back/ muscle aches and chills. Seemed to go throughout the evening 2/4. Woke up feeling better okay to work.
About 8 hrs after injection while at work I started to notice a dry sore throat and that I was kind of feverish. 5 hrs later when getting ready for bed I got chills that lasted almost an hour as I attempted to warm up. Upon waking up next morning felt very lethargic while still being sore in the arm and very feverish. That lasted all day, feel much better this morning but retained a persistent cough
This spontaneous report as received from a medical assistant refers to a 12 month old patient of unknown gender. The patient's concurrent conditions, medical history, concomitant medications, drug reactions and allergies were not reported. On 11-SEP-2018, the patient was vaccinated with improperly stored dose of VAQTA ped 0.5 ml vial (dose, frequency and route were not reported) (lot # R009953, expiry date: 12-JUN-2019) for prophylaxis. The vaccine was exposed to the temperature of 32.21 degree Fahrenheit (°F) (32F to 35 F) for 3.5 hours from 06-SEP-2018. Previous excursion was 50.37°F for 4.5 hours as recorded by a data logger. No adverse effect was reported. No product quality complaint was involved. This is one of the several reports received from the same reporter source. Sender's Comments: US-009507513-1809USA002868: Original Case: 1809USA002868; US-009507513-1902USA009324: Original Case: 1902USA009323; US-009507513-1902USA009325: Original Case: 1902USA009323; US-009507513-1902USA009326: Original Case: 1902USA009323.
I had an achy arm for a couple days after receiving the vaccine. I was exposed to COVID-19 at our local gym. I tested positive for COVID-19 in 03/2023. I had symptoms of a cold and a dry cough. I contacted my doctor and got a prescription for PAXLOVID. I tolerated the medication without any complications. As of today, I am feeling better with no lingering symptoms.
very sick; heart palpitation side effects; first vaccine at the end of March 2021; This spontaneous case was reported by a consumer and describes the occurrence of ILLNESS (very sick), PALPITATIONS (heart palpitation side effects) and PRODUCT DOSE OMISSION ISSUE (first vaccine at the end of March 2021) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    In March 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced ILLNESS (very sick), PALPITATIONS (heart palpitation side effects) and PRODUCT DOSE OMISSION ISSUE (first vaccine at the end of March 2021). At the time of the report, ILLNESS (very sick) and PALPITATIONS (heart palpitation side effects) outcome was unknown and PRODUCT DOSE OMISSION ISSUE (first vaccine at the end of March 2021) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were reported.  No treatment information was provided.
Information has been received from a nurse practitioner concerning a female patient who approximately two months ago was vaccinated with the first dose of GARDASIL (Lot number was not provided). Concomitant therapy included MENACTRA and ADACEL. The patient following receiving the third injection that day which was GARDASIL fainted or had a syncopal event. The patient immediately snapped back and recovered. The patient did not need any type of medical intervention. The patient was in the nurse's office today and the patient's mother informed the nurse that the patient after that synocopal event and after recovering had soreness in her feet for four days. The patient was eligible for the second dose of GARDASIL today but the nurse deferred the dose of GARDASIL and will be providing the second dose of GARDASIL at the next regular visit when the patient arrives. Additional information has been requested.
On 10/19/01, the pt experienced slight diarrhea. On 10/20/01 and 10/21/01, the pt experienced severe watery diarrhea, gas, weakness and general flu-like signs and symptoms. The pt denies blood or mucous in stool. The pt did not seek medical attention. He took OTC's (anti-cholinergic and Pepto-Bismol). The pt was a drug rep for many years and feels the vaccine was not manufactured correctly and is a live virus vaccine.
I have severe MGD on my left side. For 6 months, I had daily elevated temperatures. After starting Cequa, these subsided. But returned after the COVID shot. Symptoms have not subsided, seem to be getting worse.
Headache, Myalgia, Arthralgia, Fever, Discomfort @ injection site Narrative:
Shoulder pain, particularly when laying on the shoulder; stiffness; loss of mobility/range of motion limited
2 weeks after 2nd shot I had a period and have not had one in several years.